Efficacy of Double Dose Dapsone Combination Therapy in The
Total Page：16
File Type：pdf, Size：1020Kb
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 1 September 2020 doi:10.20944/preprints202009.0009.v1 1 Case Report 2 Efficacy of Double Dose Dapsone Combination 3 Therapy in the Treatment of Chronic Lyme 4 Disease/Post-Treatment Lyme Disease Syndrome 5 (PTLDS) and Associated Co-infections: A Report of 6 Three Cases 7 Richard Horowitz 1,2 and Phyllis Freeman 2,* 8 1 Member, HHS Babesia and Tick-borne Pathogens Subcommittee, Washington, D.C. 20201, USA; 9 [email protected] 10 2 Hudson Valley Healing Arts Center, Hyde Park, N.Y. 12538, USA 11 * Correspondence: [email protected]; Tel.: 1-845-229-8977 12 Received: date; Accepted: date; Published: date 13 Abstract: Three patients with multi-year histories of relapsing and remitting Lyme disease and 14 associated co-infections despite extended antibiotic therapy were each given double dose dapsone 15 combination therapy (DDD CT) for a total of 7-8 weeks. At the completion of therapy, all three 16 patients major Lyme symptoms remained in remission for a period of 25-30 months. In conclusion, 17 Double dose dapsone therapy could represent a novel and effective anti-infective strategy in 18 chronic Lyme disease/PTLDS, especially in those individuals who have failed regular dose dapsone 19 combination therapy (DDS CT) or standard antibiotic protocols. A randomized, blinded, 20 placebo-controlled trial is warranted to evaluate the efficacy of DDD CT in those individuals with 21 chronic Lyme disease/PTLDS. 22 Keywords: Lyme disease; Post-Treatment Lyme Disease Syndrome (PTLDS); dapsone combination 23 therapy (DDS CT); double dose dapsone combination therapy (DDD CT); babesiosis; persistent 24 infection 25 26 1. Introduction 27 Lyme disease affects over 300,000 Americans per year [1] [2] and at least 2 million individuals in 28 the United States have been reported to be suffering from Post-Treatment Lyme Disease Syndrome 29 (PTLDS) [3]. In Europe, Lyme borreliosis is also the most common tick-borne disease [4] and 30 worldwide estimates suggest an increase in tick-vectored disease incidence and distribution [5]. 31 Ticks can contain a broad range of bacteria (i.e., borrelia spp., rickettsia spp., tularemia), viruses (i.e., 32 tick-borne encephalitis virus, Powassan virus) and parasites (babesia)[6]. Estimates from the World 33 Health Organization suggest that 17% of human global infectious disease burden are vector-borne, 34 with Borrelia burgdorferi sensu lato complex and relapsing fever borreliosis comprising the major 35 borrelia spp. vectored by ticks [7]. Based on the geographical spread and increasing number of 36 individuals suffering from Lyme and associated tick-borne diseases (TBD’s), and significant health 37 care costs associated with treatment failures [8][9], the necessity of finding effective treatments for 38 Lyme borreliosis and associated co-infections is vitally important from a public health perspective. 39 Approximately 10-20% of individuals treated for Lyme disease with a 2-4-week course of 40 antibiotics will go on to experience chronic, persistent fatigue, musculoskeletal pain and 41 neurocognitive difficulties that persist for more than 6 months, known as Post-Treatment Lyme 42 Disease Syndrome (PTLDS) [10]. The etiology of Chronic Lyme disease/PTLDS is unknown, Antibiotics 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/antibiotics © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 1 September 2020 doi:10.20944/preprints202009.0009.v1 Antibiotics 2020, 9, x FOR PEER REVIEW 2 of 22 43 although several major hypotheses have been proposed to explain persistent symptoms, including 44 persistence of Borrelia and/or borrelial antigens, persistent tick-borne co-infections, immune 45 dysregulation, altered neural networks with central sensitization, and/or overlapping sources of 46 inflammation [11][12][13][14]. Borrelia’s ability to persist in the body has been hypothesized to take 47 place through multiple mechanisms. These include immune evasion with borrelia changing its 48 surface antigenic expression in response to host immune responses [15] [16], persistence in the 49 intracellular compartment [17] [18], and changing morphological forms in various environments [19] 50 [20] [21] [22], resulting in atypical cystic forms [23], pleomorphic round bodies (cell wall deficient, 51 L-forms) [20], as well as ‘persister’ and ‘biofilm forms’[24] [25] [26] [27] [28]. The stationary, 52 persister, and biofilm forms of Borrelia burgdorferi (Bb) have been found to be resistant to standard 53 antibiotic treatments and a cause of persistent inflammation [29][30][31]. This phenotypic plasticity 54 of Borrelia and its survival in biofilms may help to explain in part clinical conundrums and persistent 55 symptomatology [32]. 56 There have been several studies to date evaluating persister drugs and biofilm agents in the 57 treatment of Lyme disease. Most of these have been in vitro studies, using essential oils, herbal 58 compounds like Stevia, or drugs found through a search of the NCI compound collection or FDA 59 approved drug library [33][34] [35][29]. Two of these compounds, dapsone and disulfiram, which 60 are both sulfa drugs, have been found to be effective against stationary phase Borrelia burgdorferi [36] 61 [37][38] and evaluated in clinical studies. Disulfiram was found in a small case series to have a 62 positive clinical effect in three patients who required intensive open-ended antimicrobial therapy for 63 chronic relapsing neurological Lyme disease and relapsing babesiosis [39]. Dapsone combination 64 therapy (DDS CT) has been published in two, separate retrospective case series, totaling 300 65 patients, to have a positive effect on eight major Lyme symptoms, and improve treatment outcomes 66 among patients with chronic Lyme disease/PTLDS and associated coinfections in those failing 67 traditional antibiotic therapy [40][14]. 68 Success in the prior DDS CT trials was operationally defined as improvement in percent of 69 normal after 6 months on DDS CT, and failure was operationally defined as remaining the same or 70 worsening of the percentage of normal after at least 6 months of DDS CT. “Of 181 participants who 71 gave both pre-DDS and DDS percentage scores, 14 participants reported feeling worse currently 72 than they did before the DDS, 22 participants reported no difference, while all other participants 73 (145) currently reported a higher percentage of normal”[14]. Causes of potential failures of DDS CT 74 highlighted in Part 1 of our Precision Medicine study included evidence of chronic persistent 75 infection with Borrelia, Bartonella, and Mycoplasma species, as well as B. microti. These were all shown 76 to persist despite commonly prescribed courses of antibiotics or antimalarial/Babesia therapy [14]. 77 Persistence of bacteria can be explained in part by bacterial biofilms, in which cells are protected 78 from the immune system by surface exopolymers with polysaccharides [41]. Antibiotics have been 79 shown in this model to kill regular cells, leaving dormant persisters alive, and when the 80 concentration of antibiotic drops, they resuscitate and repopulate the biofilm [42]. 81 Since the dosage of dapsone in the initial two studies varied between 25 and 100 mg/day, and 82 the effect of ‘persister’ drugs like dapsone may depend on drug dependent concentrations and its 83 effect on biofilms [43], we decided to try a higher dose of dapsone (100 mg BID) for one month in 84 several patients with a history of chronic, persistent relapses. We present here three case studies of 85 individuals who took 7-8 weeks of dapsone combination therapy using hydroxychloroquine, 86 cimetidine, nystatin, a tetracycline, rifampin, and dapsone (DDS CT), where the dose of dapsone was 87 increased the second month to 100 mg BID, i.e., double dose dapsone combination therapy (DDD 88 CT). Nutritional support included N-acetyl cysteine 600 mg PO BID, alpha lipoic acid 600 mg PO 89 BID, gradually increasing doses of glutathione up to 1000-2000 mg BID by the end of the first month, 90 folinic acid (Leucovorin 25 mg PO BID month one, 25 mg TID month 2), L-methyl folate 15 mg PO 91 BID, along with three biofilm agents (Stevia, oregano oil, Biocidin) and three probiotics (Theralac, 92 Ultra Flora DF, saccharomyces boulardii). Patients signed informed consent forms that listed the major 93 side effects of dapsone combination therapy, which included Herxheimer reactions, anemia 94 secondary to folic acid inhibition (hemolytic anemia was minimized by ensuring all patients had Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 1 September 2020 doi:10.20944/preprints202009.0009.v1 Antibiotics 2020, 9, x FOR PEER REVIEW 3 of 22 95 normal levels of G-6-P-D, or they were ineligible for the trial), rashes (secondary to sulfa sensitivity) 96 and/or methemoglobinemia (secondary to increased oxidative stress and decreased heme oxygen 97 carrying capacity). Patients were instructed to get regular laboratory testing with a complete blood 98 count (CBC), comprehensive metabolic profile (CMP) and methemoglobin levels once at 100 mg of 99 dapsone, and to repeat laboratory testing weekly during the second month of higher dose therapy. 100 Any major changes in their symptoms were to be reported immediately to the first author via an 101 emergency cell phone number. After stopping all antibiotic therapy once the trial was completed, all 102 three individuals remained on biofilm agents, folic acid replacement and probiotics for the next 103 several months. All three patients remained in remission for time periods ranging between 2 and 3 104 years with no further Lyme and tickborne symptoms after completing DDD CT. 105 2. Case 1 106 This 20-year-old Black male, with a past medical history significant for Lyme disease and 107 babesiosis, as well as obsessive-compulsive disorder (OCD), became our patient in June 2017.